相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Key chemokines direct migration of immune cells in solid tumors
Karan Kohli et al.
CANCER GENE THERAPY (2022)
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Emma C. Morris et al.
NATURE REVIEWS IMMUNOLOGY (2022)
TGFβ biology in cancer progression and immunotherapy
Rik Derynck et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression
Kristen Fousek et al.
PHARMACOLOGY & THERAPEUTICS (2021)
Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
Anne Montfort et al.
CLINICAL CANCER RESEARCH (2021)
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future
Geert R. D'Haens et al.
GUT (2021)
Therapeutic Strategies for Targeting IL-1 in Cancer
Adrian Gottschlich et al.
CANCERS (2021)
Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy
Melinda L. Telli et al.
CLINICAL CANCER RESEARCH (2021)
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study
Nizar M. Tannir et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase II/III clinical results of IL-15R[alpha]Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients.
Karim Chamie et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)
David Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Chemotherapy Induces Tumor-Associated Macrophages that Aid Adaptive Immune Responses in Ovarian Cancer
Owen Heath et al.
CANCER IMMUNOLOGY RESEARCH (2021)
Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer
Sonia Missiroli et al.
CANCERS (2021)
Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy
Pedro Bule et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes
Paul B. Chapman
JOURNAL OF CLINICAL ONCOLOGY (2021)
Preliminary data from QUILT 3.055: A phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors (CPI).
John M. Wrangle et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.
Valentina Boni et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.
Omid Hamid et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
Margherita Turinetto et al.
FRONTIERS IN ONCOLOGY (2021)
A human multi-cellular model shows how platelets drive production of diseased extracellular matrix and tissue invasion
Beatrice Malacrida et al.
ISCIENCE (2021)
NHS-IL12, a Tumor-Targeting Immunocytokine
John W. Greiner et al.
IMMUNOTARGETS AND THERAPY (2021)
Interleukins in cancer: from biology to therapy
Dania Briukhovetska et al.
NATURE REVIEWS CANCER (2021)
Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7
Ji-Hae Kim et al.
BMB REPORTS (2021)
3D In Vitro Model (R)evolution: Unveiling Tumor-Stroma Interactions
Joao Rodrigues et al.
TRENDS IN CANCER (2021)
Targeting TGFβ signal transduction for cancer therapy
Sijia Liu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
Marcus Noel et al.
INVESTIGATIONAL NEW DRUGS (2020)
Biology and therapeutic potential of interleukin-10
Margarida Saraiva et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Clinical significance of chemokine receptor antagonists
Miao Miao et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2020)
First-in-human phase I study of intraperitoneally administered interferon-activated autologous monocytes in platinum-resistant or refractory ovarian cancer.
Christopher Browning Cole et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer
Thomas A. Waldmann et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies
Sara K. Daniel et al.
SEMINARS IN CANCER BIOLOGY (2020)
MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype
Nicole M. Sodir et al.
CANCER DISCOVERY (2020)
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
Hanne Lind et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
Clement Anfray et al.
CELLS (2020)
Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment
Eleni Maniati et al.
CELL REPORTS (2020)
Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines
Liuxue Sheng et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Alain P. Algazi et al.
CLINICAL CANCER RESEARCH (2020)
Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
Yoon-Koo Kang et al.
CLINICAL CANCER RESEARCH (2020)
Rationale for IL-15 superagonists in cancer immunotherapy
Karin M. Knudson et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.
Georg Martin Haag et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab et al.
CANCER DISCOVERY (2020)
Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development
Brooke Benner et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
IL-15 in the Combination Immunotherapy of Cancer
Thomas A. Waldmann et al.
FRONTIERS IN IMMUNOLOGY (2020)
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
Jared E. Lopes et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
Changhoon Yoo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Kurt A. Schalper et al.
NATURE MEDICINE (2020)
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bruno Bockorny et al.
NATURE MEDICINE (2020)
Translating IL-6 biology into effective treatments
Ernest H. Choy et al.
NATURE REVIEWS RHEUMATOLOGY (2020)
y Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study
Dmitriy Zamarin et al.
CLINICAL CANCER RESEARCH (2020)
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
Byoung Chul Cho et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
Joan How et al.
CANCERS (2020)
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma
Paolo Strati et al.
BLOOD ADVANCES (2020)
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S. Grasso et al.
CANCER CELL (2020)
Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: A systematic review and network meta-analysis
Jun-Lin Lu et al.
CANCER MEDICINE (2020)
Localized Interleukin-12 for Cancer Immunotherapy
Khue G. Nguyen et al.
FRONTIERS IN IMMUNOLOGY (2020)
Advances of CCR5 antagonists: From small molecules to macromolecules
Baowen Qi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy
Ying Yang et al.
CANCERS (2020)
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
Daniele Biasci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4
Jan Korbecki et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
A randomized phase II trial of reparixin, a CXCR1 inhibitor, in combination with paclitaxel in the treatment of mTNBC
Lori J. Goldstein et al.
CANCER RESEARCH (2020)
Tumors establish resistance to immunotherapy by regulating T-reg recruitment via CCR4
Lisa A. Marshall et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy A Systematic Review and Meta-Analysis of Observational Studies
Dejan Micic et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2019)
Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity
Elise Alspach et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2019)
Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hans Carl Hasselbalch et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors
Tiziano Ongaro et al.
JOURNAL OF BIOTECHNOLOGY (2019)
Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics
Karen Autio et al.
CURRENT ONCOLOGY REPORTS (2019)
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages
C. A. Gomez-Roca et al.
ANNALS OF ONCOLOGY (2019)
The Immunobiology of the Interleukin-12 Family: Room for Discovery
Elia D. Tait Wojno et al.
IMMUNITY (2019)
Shared and Distinct Functions of Type I and Type III Interferons
Helen M. Lazear et al.
IMMUNITY (2019)
MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).
Philippe Alexandre Cassier et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Elisabeth Perez-Ruiz et al.
NATURE (2019)
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel 1L2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Salah-Eddine Bentebibel et al.
CANCER DISCOVERY (2019)
Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)
Celeste Lebbe et al.
EUROPEAN JOURNAL OF CANCER (2019)
Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation
Shabnam Shalapour et al.
IMMUNITY (2019)
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
William D. Tap et al.
LANCET (2019)
Cancer modeling meets human organoid technology
David Tuveson et al.
SCIENCE (2019)
Leukocyte Adhesion: Reconceptualizing Chemokine Presentation by Glycosaminoglycans
Gerard J. Graham et al.
TRENDS IN IMMUNOLOGY (2019)
Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial
Shihong Zhang et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Tuning the Tumor Myeloid Microenvironment to Fight Cancer
Nadine S. Jahchan et al.
FRONTIERS IN IMMUNOLOGY (2019)
A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)
Jeffrey Melson Clarke et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors
Toshihiko Doi et al.
CLINICAL CANCER RESEARCH (2019)
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
Aung Naing et al.
LANCET ONCOLOGY (2019)
Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?
Sumanta Pal et al.
LANCET ONCOLOGY (2019)
Modulators of CXCR4 and CXCR7/ACKR3 Function
Ilze Adlere et al.
MOLECULAR PHARMACOLOGY (2019)
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
Marijo Bilusic et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
U. Dafni et al.
ANNALS OF ONCOLOGY (2019)
Bempegaldesleukin (NKTR-214): a CD-122-biased IL-2 receptor agonist for cancer immunotherapy
Stephen K. Doberstein
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma A systematic review and meta-analysis
Genmao Cao et al.
MEDICINE (2019)
Flip the coin: IL-7 and IL-7R in health and disease
Joao T. Barata et al.
NATURE IMMUNOLOGY (2019)
Immune regulation and cytotoxic T cell activation of IL-10 agonists-Preclinical and clinical experience
Martin Oft
SEMINARS IN IMMUNOLOGY (2019)
NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis
Nour Ershaid et al.
NATURE COMMUNICATIONS (2019)
Fine-Tuning Cytokine Signals
Jian-Xin Lin et al.
Annual Review of Immunology (2019)
Cytokines in clinical cancer immunotherapy
Pedro Berraondo et al.
BRITISH JOURNAL OF CANCER (2019)
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
Ezra E. W. Cohen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines
Connor J. Dwyer et al.
FRONTIERS IN IMMUNOLOGY (2019)
Phase I/II dose escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.
William Ho et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2019)
Interleukin-6 Family Cytokines
Stefan Rose-John
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
Cytokines in Cancer Immunotherapy
Thomas A. Waldmann
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer
Te-Chia Wu et al.
CANCER RESEARCH (2018)
Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma
Eudocia Q. Lee et al.
CLINICAL CANCER RESEARCH (2018)
Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
Brandon W. Higgs et al.
CLINICAL CANCER RESEARCH (2018)
Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.
David Linehan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M. Wrangle et al.
LANCET ONCOLOGY (2018)
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
Sonia Pernas et al.
LANCET ONCOLOGY (2018)
Interleukin-6 and prostate cancer: Current developments and unsolved questions
Zoran Culig et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
A phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer
Dung Le et al.
CANCER RESEARCH (2018)
Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) plus nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications.
Michael Carleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.
Adi Diab et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Youn H. Kim et al.
LANCET ONCOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
Aung Naing et al.
CANCER CELL (2018)
Targeting macrophages: therapeutic approaches in cancer
Luca Cassetta et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
FADD at the Crossroads between Cancer and Inflammation
Sara Mouasni et al.
TRENDS IN IMMUNOLOGY (2018)
Anakinra Therapy for Non-cancer Inflammatory Diseases
Giulio Cavalli et al.
FRONTIERS IN PHARMACOLOGY (2018)
Neoadjuvant ipilimumab (3mg/kg or 10mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
Ahmad Tarhini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
NF-κB, inflammation, immunity and cancer: coming of age
Koji Taniguchi et al.
NATURE REVIEWS IMMUNOLOGY (2018)
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Jeffrey S. Miller et al.
CLINICAL CANCER RESEARCH (2018)
Interleukin-1α as an intracellular alarmin in cancer biology
Elena Voronov et al.
SEMINARS IN IMMUNOLOGY (2018)
Overall survival of PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TGF-β Family Signaling in the Control of Cell Proliferation and Survival
Yun Zhang et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2017)
Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis
Natalie J. Ives et al.
EUROPEAN JOURNAL OF CANCER (2017)
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer
Chiara Berlato et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
Roger Chou et al.
JOURNAL OF UROLOGY (2017)
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker et al.
LANCET (2017)
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer
Ravi Salgia et al.
LUNG CANCER (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Michael A. Cannarile et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Oncolytic viral Therapy for Mesothelioma
Daniel F. Pease et al.
FRONTIERS IN ONCOLOGY (2017)
Targeting the Tumor Microenvironment by Intervention in Interleukin-1 Biology
Elena Voronov et al.
CURRENT PHARMACEUTICAL DESIGN (2017)
Interleukin-8 in cancer pathogenesis, treatment and follow-up
Carlos Alfaro et al.
CANCER TREATMENT REVIEWS (2017)
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos et al.
CLINICAL CANCER RESEARCH (2017)
Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer
Anne F. Schott et al.
CLINICAL CANCER RESEARCH (2017)
A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors
Laura W. Goff et al.
CLINICAL CANCER RESEARCH (2016)
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
Nicholas Butowski et al.
NEURO-ONCOLOGY (2016)
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinomaaEuro
M. Simonelli et al.
ANNALS OF ONCOLOGY (2016)
A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas
Megan C. Duggan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model
Antonio Sacco et al.
CANCER RESEARCH (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
Steffen Bohm et al.
CLINICAL CANCER RESEARCH (2016)
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Timothy M. Nywening et al.
LANCET ONCOLOGY (2016)
A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)
John D. Hainsworth et al.
TARGETED ONCOLOGY (2016)
Targeting the CCL2-CCR2 signaling axis in cancer metastasis
Su Yin Lim et al.
ONCOTARGET (2016)
A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
Andrew S. Brohl et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC)
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Interleukin-6 as a Therapeutic Target
Jean-Francois Rossi et al.
CLINICAL CANCER RESEARCH (2015)
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
Mythili Koneru et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Louise K. Mercer et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study
Irene Brana et al.
TARGETED ONCOLOGY (2015)
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
Carola H. Ries et al.
CANCER CELL (2014)
Interleukin 12: still a promising candidate for tumor immunotherapy?
Witold Lasek et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
Matthew D. Galsky et al.
CLINICAL CANCER RESEARCH (2014)
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial
A. Necchi et al.
INVESTIGATIONAL NEW DRUGS (2014)
Cancer-related inflammation and treatment effectiveness
Connie I. Diakos et al.
LANCET ONCOLOGY (2014)
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
Frits van Rhee et al.
LANCET ONCOLOGY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
John C. Morris et al.
PLOS ONE (2014)
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
Koji Taniguchi et al.
SEMINARS IN IMMUNOLOGY (2014)
The immunocytokine NHS-IL12 as a potential cancer therapeutic
Jonathan Fallon et al.
ONCOTARGET (2014)
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
Janice P. Dutcher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
Roxanne Payne et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
A review on CXCR4/CXCL12 axis in oncology: No place to hide
Urszula M. Domanska et al.
EUROPEAN JOURNAL OF CANCER (2013)
Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
Wei Liao et al.
IMMUNITY (2013)
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
Kenneth J. Pienta et al.
INVESTIGATIONAL NEW DRUGS (2013)
Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey
Bharat B. Aggarwal et al.
BLOOD (2012)
IL-10 Directly Activates and Expands Tumor-Resident CD8+ T Cells without De Novo Infiltration from Secondary Lymphoid Organs
Jan Emmerich et al.
CANCER RESEARCH (2012)
Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma
Ahmad A. Tarhini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Paraneoplastic Thrombocytosis in Ovarian Cancer
Rebecca L. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma
John H. Sampson et al.
PLOS ONE (2012)
Cancer-related inflammation: Common themes and therapeutic opportunities
Frances R. Balkwill et al.
SEMINARS IN CANCER BIOLOGY (2012)
The role of interleukin-2 during homeostasis and activation of the immune system
Onur Boyman et al.
NATURE REVIEWS IMMUNOLOGY (2012)
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
John B. Mumm et al.
CANCER CELL (2011)
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
Jermaine Coward et al.
CLINICAL CANCER RESEARCH (2011)
Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
Joannes F. M. Jacobs et al.
CLINICAL CANCER RESEARCH (2010)
Clinical Use of Anti-CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells
Andrew J. Rech et al.
CANCER VACCINES (2009)
Role of cytokine therapy for Renal Cell Carcinoma in the era of targeted agents
Sebastien J. Hotte et al.
Current Oncology (2009)
The role of differential expression of human interferon-A genes in antiviral immunity
Pierre Genin et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2009)
New insights into the regulation of T cells by γc family cytokines
Yrina Rochman et al.
NATURE REVIEWS IMMUNOLOGY (2009)
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer
E. R. Brown et al.
ANNALS OF ONCOLOGY (2008)
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival
David S. Alberts et al.
GYNECOLOGIC ONCOLOGY (2008)
Interferons at age 50: past, current and future impact on biomedicine
Ernest C. Borden et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Tumor necrosis factor α as a new target for renal cell carcinoma:: Two sequential phase II trials of infliximab at standard and high dose
Michelle L. Harrison et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Interleukin-12: Biological properties and clinical application
Michele Del Vecchio et al.
CLINICAL CANCER RESEARCH (2007)
A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides
Madeleine Duvic et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma
Richard F. Little et al.
BLOOD (2006)
Side effects of interferon-α therapy
S Sleijfer et al.
PHARMACY WORLD & SCIENCE (2005)
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease
N Nishimoto et al.
BLOOD (2005)
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene
MG Borrello et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
DF McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease
A Younes et al.
CLINICAL CANCER RESEARCH (2004)
IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer
FR Greten et al.
CELL (2004)
The significance of cancer cell expression of the chemokine receptor CXCR4
F Balkwill
SEMINARS IN CANCER BIOLOGY (2004)
Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials
MB Lens et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
